Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation.

Arta M. Monjazeb,Anita Giobbie-Hurder,Ana Lako,Anteneh Tesfaye,Amanda Stroiney,Ryan D. Gentzler,Salma K. Jabbour,Olatunji B. Alese,Osama E. Rahma,James M. Cleary,Elad Sharon,David Raben,Harvey J. Mamon,Howard Streicher,Helen X. Chen,Mansoor M. Ahmed,Evisa Gjini,Scott J. Rodig,F. Stephen Hodi,Jonathan D. Schoenfeld

Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation.

2019

49Background: Pre-clinical and clinical evidence support immune effects of targeted radiation (RT) resulting in synergy with immune checkpoint therapy. However, prospective data are lacking in rega...

Keywords:

PD-L1
Oncology
Pathology
Medicine
Colorectal cancer
Randomized controlled trial
Internal medicine
CTLA-4
immune effects
prospective data
low dose
Immune checkpoint

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations